Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC

Non-small Cell Lung Cancer Clinical Trial

— CLASSIC5  

Official title:

Chemotherapy Plus Immune Checkpoint Inhibitor With or Without Bevacizumab After Disease Progression With First-line Alectinib of Advanced ALK-rearranged Non-small Cell Lung Cancer With 5'-ALK

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04997382
• Other study ID #: ALICE
• Status: Completed
• Phase: Phase 2
• Start date: August 17, 2021
• Est. completion date: January 31, 2024

Study information

• Verified date: May 2024
• Source: Hunan Province Tumor Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study aimed to investigate the combination of chemotherapy and immunotherapy for patients with metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) who had failed from first line Alectinib. Additionally, available biological samples such as blood and tumor tissues were collected to explore potential biomarkers, including but not limited to RNA-seq, whole-exome sequencing (WES), whole-genome sequencing (WGS), immunohistochemistry, and multiplex immunofluorescence.

Description:

1. The investigators collected data from patients with metastatic ALK fusion-positive non-small cell lung cancer (NSCLC) who received first-line Alectinib treatment between April 2017 and July 2021. Our analysis aimed to assess their clinical outcomes and explore the impact of 5' ALK on the treatment response to Alectinib.

2. For patients who experienced disease progression after August 2021, they were treated with a combination of chemotherapy and PD-1 monoclonal antibodies with/without Bevacizumab or chemotherapy alone with/without Bevacizumab was observed and recorded data on progression-free survival (PFS), objective response rate (ORR), duration of response (DOR), and overall survival (OS) for these patients.

3. The investigators collected pre-treatment biological samples for biomarker analysis, including FFPE samples for whole-genome sequencing (WGS), whole-exome sequencing (WES), RNA-seq, and multiplex fluorescence analysis. FFPE samples were also collected for PD-L1 testing. Additionally, pre-treatment blood samples were collected for cytokine analysis, as well as tumor mutational burden (TMB) and T-cell receptor (TCR) testing. The investigators aimed to evaluate the differences in these results between 3' ALK and 5' ALK.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 108
• Est. completion date: January 31, 2024
• Est. primary completion date: January 31, 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. =18,Advanced Non-small Cell Lung Cancer Confirmed by Histopathology

2. ALK -arreaged confirmed by NGS;

3. Received first line treatment Alectinib;

4. Progressed from first-line alectinib;

5. ECOG 0-1;

6. Predicted survival = 12 weeks;

7. Adequate bone marrow hematopoiesis and organ function;

8. Presence of measurable lesions according to RECIST 1.1;

9. Subjects with stable brain metastases may be included in the study.

10. Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.

Exclusion Criteria:

1. Patient who do not have the samples for NGS to confirmed ALK status.

2. Subjects who have received any of the following treatments must be excluded:

• Treatment with molecules such as EGFR, VEGFR antibodies within 4 weeks prior to the first dose of study drug.

• Have received radiation within 14 days prior to the first dose or have not recovered from radiation-related toxicity. Chest and extra-brain palliative radiotherapy, stereotactic radiosurgery, and stereotactic body radiotherapy may be performed 7 days prior to the first dose.

3. Presence of spinal cord compression or meningeal metastasis.

4. History of other malignant tumors within 2 years.

5. Adverse events (except alopecia of any degree) of CTCAE > grade 1 due to prior treatment (e.g., adjuvant chemotherapy, radiotherapy, etc.) prior to the first dose.

6. History of stroke or intracranial hemorrhage within 6 months prior to the first dose.

7. The presence of any severe or poorly controlled systemic disease, including poorly controlled hypertension and active bleeding in the judgment of the investigator.

8. Past history of interstitial lung disease, drug-induced interstitial lung disease, radiation pneumonitis requiring steroid therapy or interstitial lung disease with active clinical symptoms, immune pneumonia caused by immunotherapy.

9. Refractory nausea and vomiting, chronic gastrointestinal disease, difficulty swallowing drugs, or inability to adequately absorb sunvozertinib or anlotinib due to previous bowel resection.

10. Live vaccine was given 2 weeks before the first medication.

11. Women who are breastfeeding or pregnant.

12. Hypersensitivity to the test drug and the ingredients.

13. Other conditions assessed by the investigator to be unsuitable for participation in the study.

Related Conditions & MeSH terms

• Carcinoma, Non-Small-Cell Lung
• Lung Neoplasms
• Non-small Cell Lung Cancer

Intervention

Drug:
• Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab
Immune Checkpoint Inhibitors, for pembrolizumab, 200mg ivgtt once,every 21 days; for Atezolizumab, 1200mg vgtt once,every 21 days.
• Chemotherapy alone or Chemotherapy with or without Bevacizumab
Bevacizumab, 15mg/kg,every 21 day

Locations

Country	Name	City	State
China	Hunan Cancer Hospital	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
Hunan Province Tumor Hospital

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	PFS	Progression free survival time	From first dose until 28 days after the last dose, up to 24 months
Secondary	OS	Overall survival time	Time from first subject dose to study completion, or up to 48 months